CAMBRIDGE, Mass., Jan. 10, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that David Spellman, Chief Financial Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect Conference, which will take place virtually January 10-13, 2022.  

An audio replay of the fireside chat will be available through the Investors section of Akebia's website at https://ir.akebia.com for approximately 90 days following the conference.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
Mcarrasco@akebia.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-hc-wainwright-bioconnect-conference-301456833.html

SOURCE Akebia Therapeutics